Moomoo AI 已提取核心信息
On February 12, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the existing registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company also announced a primary offering of up to 8,923,935 shares of common stock upon the exercise of warrants and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. The warrants, exercisable at $11.50 per share, include Public Warrants, Private Warrants, and Convertible Note Warrants. ProSomnus, a manufacturer of oral appliance therapy devices for obstructive sleep apnea, will not receive proceeds from the sale of securities by the Selling Securityholders, except for potential proceeds from the exercise of warrants. The company's common stock and public warrants are listed on the Nasdaq under the symbols 'OSA' and 'OSAAW,' respectively.
On February 12, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the existing registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company also announced a primary offering of up to 8,923,935 shares of common stock upon the exercise of warrants and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. The warrants, exercisable at $11.50 per share, include Public Warrants, Private Warrants, and Convertible Note Warrants. ProSomnus, a manufacturer of oral appliance therapy devices for obstructive sleep apnea, will not receive proceeds from the sale of securities by the Selling Securityholders, except for potential proceeds from the exercise of warrants. The company's common stock and public warrants are listed on the Nasdaq under the symbols 'OSA' and 'OSAAW,' respectively.
2024年2月12日，特拉华州的一家公司ProSomnus, Inc. 向美国证券交易委员会（SEC）提交了S-3表格S-1的生效后修正案。该修正案旨在将现有的注册声明转换为S-3表格的注册声明，并将先前注册的可转换票据股票从注册中删除，其中230,494股已出售。该公司还宣布在行使认股权证时首次发行最多8,923,935股普通股，并二次发行最多9,850,363股普通股和最多2,411,848份认股权证。认股权证可按每股11.50美元的价格行使，包括公开认股权证、私人认股权证和可转换票据认股权证。ProsomNUS是阻塞性睡眠呼吸暂停的口服器械治疗设备的制造商，除行使认股权证的潜在收益外，不会获得出售证券持有人出售证券的收益。该公司的普通股和公开认股权证分别在纳斯达克上市，代码分别为 “OSA” 和 “OSAAW”。
2024年2月12日，特拉华州的一家公司ProSomnus, Inc. 向美国证券交易委员会（SEC）提交了S-3表格S-1的生效后修正案。该修正案旨在将现有的注册声明转换为S-3表格的注册声明，并将先前注册的可转换票据股票从注册中删除，其中230,494股已出售。该公司还宣布在行使认股权证时首次发行最多8,923,935股普通股，并二次发行最多9,850,363股普通股和最多2,411,848份认股权证。认股权证可按每股11.50美元的价格行使，包括公开认股权证、私人认股权证和可转换票据认股权证。ProsomNUS是阻塞性睡眠呼吸暂停的口服器械治疗设备的制造商，除行使认股权证的潜在收益外，不会获得出售证券持有人出售证券的收益。该公司的普通股和公开认股权证分别在纳斯达克上市，代码分别为 “OSA” 和 “OSAAW”。
有用
没用